Nasdaq · CIK 0001160308
SVRA Savara Inc
Insider trading from SEC Form 4. Last filing 16 d ago. Close $4.92 on Oct 9, 2026, +46% from the 52-week low and -29% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
SVRAOct 9, 2026 · close 4.92
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Savara Inc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | Richard J Hawkins director sell | $27k 8,000 shares | -11% | - | |
| 46Moderate | David L Lowrance Chief Financial Officer sell | $83k 25,000 shares | -6% | - | |
| 52Moderate | Matthew Pauls CHIEF EXECUTIVE OFFICER sell | $181k 54,702 shares | -3% | - | |
| 33Weak | Joseph S McCracken director buy | $59k 20,000 shares | +10% | - | |
| 37Weak | David A Ramsay director buy | $288k 100,000 shares | +4% | - |
Transactions
The last 29 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 24, 2026 | Braden C. Parker Chief Commercial Officer | FTax withholding Common Stock | -29,323 | $5.07 | $149k | 75,677 | 16 d ago |
| Dec 12, 2024 | An van Es-Johansson director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 62,500 | Dec 16, 2024 |
| Dec 12, 2024 | David A Ramsay director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 2,363,642 | Dec 16, 2024 |
| Dec 12, 2024 | Raymond Dennis Pratt Chief Medical Officer | AGrant or award Common Stock | +80,000 | $0.00 | $0 | 340,050 | Dec 16, 2024 |
| Dec 12, 2024 | Matthew Pauls CHIEF EXECUTIVE OFFICER | AGrant or award Common Stock | +400,000 | $0.00 | $0 | 1,683,674 | Dec 16, 2024 |
| Dec 12, 2024 | Nevan C Elam director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 62,500 | Dec 16, 2024 |
| Dec 12, 2024 | Anne Erickson Chief Business Officer | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 452,935 | Dec 16, 2024 |
| Dec 12, 2024 | Braden C. Parker Chief Commercial Officer | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 105,000 | Dec 16, 2024 |
| Dec 12, 2024 | Richard J Hawkins director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 75,241 | Dec 16, 2024 |
| Dec 12, 2024 | David L Lowrance Chief Financial Officer | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 442,355 | Dec 16, 2024 |
| Dec 12, 2024 | Joseph S McCracken director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 250,837 | Dec 16, 2024 |
| Dec 12, 2024 | Robert Matthew Lutz Chief Operating Officer | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 400,000 | Dec 16, 2024 |
| Dec 16, 2024 | Richard J Hawkins director | SOpen-market sale Common Stock | -8,000 | $3.32 | $27k | 67,241 | Dec 16, 2024 |
| Dec 12, 2024 | Raymond Dennis Pratt Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +280,000 | $0.00 | $0 | 280,000 | Dec 16, 2024 |
| Dec 12, 2024 | Braden C. Parker Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Dec 16, 2024 |
| Dec 12, 2024 | Robert Matthew Lutz Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 16, 2024 |
| Dec 13, 2024 | Matthew Pauls CHIEF EXECUTIVE OFFICER | FTax withholding Common Stock | -92,593 | $3.21 | $297k | 1,591,081 | Dec 16, 2024 |
| Dec 13, 2024 | David L Lowrance Chief Financial Officer | GGift Common Stock | -12,000 | $0.00 | $0 | 430,355 | Dec 16, 2024 |
| Dec 13, 2024 | Anne Erickson Chief Business Officer | FTax withholding Common Stock | -18,263 | $3.21 | $59k | 434,672 | Dec 16, 2024 |
| Dec 12, 2024 | Anne Erickson Chief Business Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 16, 2024 |
| Dec 13, 2024 | David L Lowrance Chief Financial Officer | FTax withholding Common Stock | -24,350 | $3.21 | $78k | 406,005 | Dec 16, 2024 |
| Dec 16, 2024 | Matthew Pauls CHIEF EXECUTIVE OFFICER | SOpen-market sale Common Stock | -54,702 | $3.31 | $181k | 1,536,379 | Dec 16, 2024 |
| Dec 12, 2024 | Matthew Pauls CHIEF EXECUTIVE OFFICER | AGrant or award Stock Option (Right to Buy)derivative | +900,000 | $0.00 | $0 | 900,000 | Dec 16, 2024 |
| Dec 16, 2024 | David L Lowrance Chief Financial Officer | SOpen-market sale Common Stock | -25,000 | $3.33 | $83k | 381,005 | Dec 16, 2024 |
| Dec 12, 2024 | David L Lowrance Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Dec 16, 2024 |
| Nov 19, 2024 | Joseph S McCracken director | POpen-market purchase Common Stock | +20,000 | $2.95 | $59k | 210,837 | Nov 20, 2024 |
| Nov 18, 2024 | David A Ramsay director | POpen-market purchase Common Stock | +100,000 | $2.88 | $288k | 2,323,642 | Nov 18, 2024 |
| Nov 10, 2024 | Raymond Dennis Pratt Chief Medical Officer | FTax withholding Common Stock | -49,950 | $3.97 | $198k | 260,050 | Nov 12, 2024 |
| Oct 21, 2024 | Anne Erickson Chief Business Officer | FTax withholding Common Stock | -381 | $3.57 | $1,360 | 352,935 | Oct 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Nevan C Elamdirector, ceo, officer
- Anne EricksonChief Business Officer
- Richard J Hawkinsceo, officer, director
- David L LowranceChief Financial Officer
- Robert Matthew LutzChief Operating Officer
- Joseph S McCrackendirector
- Braden C. ParkerChief Commercial Officer
- Matthew PaulsCHIEF EXECUTIVE OFFICER
- Raymond Dennis PrattChief Medical Officer
- David A Ramsaydirector
- An van Es-Johanssondirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.